Abstract 4757
Background
The challenge faced by the cancer patient is access to care and for the health system, thenon-availability of qualified personnel. Besides financial issues, patients face challenges of finding a cancer center. Governments are keen to offer universal health coverage but are in need of sustainable systems. A novel healthcare delivery system was designed and has been operational in several states of India.
Methods
General duty medical officers and nurses from government district hospitals were trained in oncology for one month. Various administrative reforms, restructuring and techno-mentoring (constant, 24x7, mentorship using WhatsAppR, Telephonic communication, regular continuing medical education) were used to create a system of health care delivery in oncology. The drug distribution system was changed to include essential oncology drugs.
Results
A district cancer care programme has been initiated in six states of India, involving 157 hospitals constituting about 20 % of the nation. The hospital has a nodal cancer unit, with nodal cancer officer and nurse in charge to deliver cancer services, such as counselling at all stages of care, assistance in diagnostics, (which may vary from biopsy to scan to tumor markers), follow up care, palliative care, end of life care and, most importantly, chemotherapy. A patient from the district has a choice of conitnuum of care at local hospital to which he is used. He can visit more frequently with no cost involved. This system change and empowerment has allowed the government to bring care closer to the facility and help patients gain access. A satisfaction survey done amongst patients shows there is a strong willingness to follow in districts.This is saving thousand of families from impoverishment. The creation of a system of cancer care delivery has led to other states following this example. From one state it has gone to six states,(population coverage of around 300 million).
Conclusions
Primary care physicians can be effectively empowered to offer specialised cancer care in government-run facilities. This duplicable, sustainable model (Pendharkar model) using existing human resources can be used by many countries fighting with shortages of personnel and access issues.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dinesh Pendharkar.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3469 - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.
Presenter: Celine Boutros
Session: Poster Display session 3
Resources:
Abstract
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract